# Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.

> PubMed lists PMID 40816230 in Molecular genetics and metabolism as Journal Article, Case Reports, Review, with publication-date metadata of 2025-08-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40816230-elamipretide:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-11-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40816230-elamipretide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-40816230-elamipretide-v1.json
- Content SHA-256: `b87992aa28c10e4ddbbc3086db3181562693052579ec535a6625e29558b70d00`

## Claims and source pins

### Headline

Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report. ([`pubmed-observation-pmid-40816230-2025-11-18-506865bd302d`](#source-pubmed-observation-pmid-40816230-2025-11-18-506865bd302d))

### Summary

PubMed lists PMID 40816230 in Molecular genetics and metabolism as Journal Article, Case Reports, Review, with publication-date metadata of 2025-08-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40816230-2025-11-18-506865bd302d`](#source-pubmed-observation-pmid-40816230-2025-11-18-506865bd302d))

### Paragraph 1

PubMed lists PMID 40816230 in Molecular genetics and metabolism as Journal Article, Case Reports, Review, with publication-date metadata of 2025-08-11 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40816230-2025-11-18-506865bd302d`](#source-pubmed-observation-pmid-40816230-2025-11-18-506865bd302d))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40816230-2025-11-18-506865bd302d`](#source-pubmed-observation-pmid-40816230-2025-11-18-506865bd302d))

## Sources

<a id="source-pubmed-observation-pmid-40816230-2025-11-18-506865bd302d"></a>
- **Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report. · retained source version 1:2025-11-18:current:506865bd302d203673f4913d365ef6fe2adfbf85cbe80cf03e09b744cecfc857** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40816230/) (`pubmed-observation-pmid-40816230-2025-11-18-506865bd302d`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-40816230-elamipretide-v1.json SHA-256: b87992aa28c10e4ddbbc3086db3181562693052579ec535a6625e29558b70d00.